Cassava Sciences, Inc.

Cassava Sciences, Inc. (SAVA) reported a net loss of $91.0 million for the fiscal year ended December 31, 2025, with no revenue generated from product sales. The company's net cash used in operating activities was $32.3 million. Total assets stood at $118.4 million, with cash and cash equivalents of $95.5 million. The accumulated deficit increased to $496.1 million. The company's primary focus shifted from its discontinued Alzheimer's disease program to developing simufilam for Tuberous Sclerosis Complex (TSC)-related epilepsy, though this program is currently under a full clinical hold by the FDA. Management believes existing cash resources are sufficient to fund operations for at least the next 12 months.

Key Takeaways